Ambient

The Cannabinoid receptor 2 (CNR2) is a G_i/o-coupled GPCR expressed in spleen, tonsils, bone marrow and peripheral blood leukocytes. There is one report that cannabinoid-induced inhibition of helper T cell activation is lost in macrophages obtained from CNR2 knockout mice. CNR2 is a potential therapeutic target in the treatment of various disease conditions, such as pain, multiple sclerosis, vascular disease, Parkinson’s disease, and other central nerve system disorders.

Cholecystokinin (CCK)-A and CCK-B receptors are highly homologous members of the seven transmembrane domain G-protein-coupled receptor super-family. Peptides in the cholecystokinin (CCK) family have a variety of biological functions in the central and peripheral nervous systems as well as in the gastrointestinal tract. The CCKA receptor has a more limited distribution with the highest densities in the hypothalamic nuclei, areas of the hippocampus, the septum, dorsal motor vagal nucleus, and interpeduncular nucleus of the brain stem. It also occurs in numerous gastro-intestinal tissues. Binding of ligands to CCK1 stimulates mobilization of intracellular calcium by activation of Gq/11. CCKA receptors affect satiety, pancreatitis, and gut motility and have growth-promoting effects on some tumors.

Cholecystokinins (CCK) are derived from preprocholecystokinin. They are widely expressed in gastrointestinal tissues and in the CNS. There are two cholecystokinin receptors, referred to as A and B (CCKAR and CCKBR). CCKBR can be activated by the smaller CCK-4 (7, 8). In the CNS, CCKBR has been implicated in anxiety, depression, schizophrenia, depression, and opioid analgesia. In the stomach, CCK2 mediates gastrin-stimulated gastric acid secretion.

Cluster of Differentiation 112 (CD112), also known as poliovirus receptor related protein 2 (PVRL2 or PRR2), is a single-pass type I transmembrane glycoprotein belonging to the Immunoglobulin superfamily. CD112 protein also serves as an entry for certain mutant strains of herpes simplex virus and pseudorabies virus, and thus is involved in cell to cell spreading of these viruses. CD112 protein has been identified as the ligand for DNAM-1 (CD226), and the interaction of CD226/CD112 protein can induce NK cell- and CD8+ T cell-mediated cytotoxicity and cytokine secretion. CD112 has been regarded as a critical component in allergic reactions, and accordingly may function as a novel target for anti-allergic therapy.

CD155, commonly known as PVR (poliovirus receptor) and Necl-5 (nectin-like molecule-5), is a type I transmembrane single-span glycoprotein, and belongs to the nectins and nectin-like (Necl) subfamily. CD155 was originally identified based on its ability to mediate the cell attachment and entry of poliovirus (PV), an etiologic agent of the central nervous system disease poliomyelitis. The normal cellular function is in the establishment of intercellular adherens junctions between epithelial cells. CD155 may assist in an efficient humoral immune response generated within the intestinal immune system. It’s been shown that CD155 can be recognized and bind by DNAM-1 and CD96, which promotes the adhension, migration and NK-cell killing. Thus, inducing cell-mediated tumor-specific immunity.

Recombinant CHO-K1 cells stably overexpress low affinity immunoglobulin gamma Fc region receptor III-A (FcγRIIIa / CD16A 158F) complex on the cell surface, including 1 alpha chain and 2 gamma chains. The surface expression of CD16A is validated by FACS analysis. This stable cell line product is designed for measuring binding affinity and stability of the Fc region of antibodies, Fc fusion proteins, or antibody based biologics that bind with CD16A 158F. GenScript also offers a stable cell line expressing the CD16A of 158V allotype (Cat. No. M00597) for FcγRIIIa polymorphism study.

Recombinant CHO-K1 cells stably express low affinity immunoglobulin gamma Fc region receptor III-A (FcγRIIIa / CD16A 158V) complex on the cell surface, including 1 alpha chain and 2 gamma chains. The surface expression of CD16A is validated by FACS analysis. This stable cell line product is designed for measuring the binding affinity and stability of the Fc region of antibodies, Fc fusion proteins, or antibody based biologics that bind with CD16A 158V. GenScript also offers a stable cell line expressing the CD16A of 158F allotype (Cat. No. M00598) for FcγRIIIa polymorphism study.

Recombinant CHO-K1 cells stably overexpress human Fc fragment of IgG receptor IIIb (FcγRIIIb / CD16B NA1). The surface expression of CD16B NA1 is validated by FACS analysis. This stable cell line product is designed for measuring binding affinity and stability of Fc region of antibodies, Fc fusion proteins, or antibody based biologics that bind with CD16B during biologics research and development.

Cell surface glycoprotein CD200 receptor 1 is a protein that in humans is encoded by the CD200R1 gene. This gene encodes a receptor for the OX-2 membrane glycoprotein. Both the receptor and substrate are cell surface glycoproteins containing two immunoglobulin-like domains. This receptor is restricted to the surfaces of myeloid lineage cells and the receptor-substrate interaction may function as a myeloid downregulatory signal. Mouse studies of a related gene suggest that this interaction may control myeloid function in a tissue-specific manner.

Recombinant CHO-K1 cells stably overexpress immunoglobulin gamma Fc region receptor II-a (FcγRIIa / CD32A 131Arg). The surface expression of CD32A 131Arg is validated by FACS analysis. This stable cell line product is designed for measuring binding affinity and stability of antibody based biologics binding with CD32A 131Arg. GenScript offers both CD32A 131Arg stable cell line and CD32A 131His stable cell line (Cat. No. M00589) for FcγRIIa polymorphism study.

Recombinant CHO-K1 cells stably overexpress low affinity immunoglobulin gamma Fc region receptor II-b (FcγRIIb / CD32B 232Thr). The surface expression of CD32B 232Thr is validated by FACS analysis. This stable cell line product is designed for measuring binding affinity and stability of Fc region of antibodies, Fc fusion proteins, or antibody based biologics that bind with CD32B 232Ile. GenScript also offers CD32B 232Ile overexpression stable cell line (Cat. No. M00587) for FcγRIIb polymorphism study.

Recombinant CHO-K1 cells stably overexpress low affinity immunoglobulin gamma Fc region receptor II-b (FcγRIIb / CD32B 232Ile). The surface expression of CD32B 232Ile is validated by FACS analysis. This stable cell line product is designed for measuring binding affinity and stability of antibody based biologics binding with CD32B 232Ile. GenScript offers both CD32B 232Ile expressing stable cell line and CD32B 232Thr expressing stable cell line (Cat. No. M00600) for FcγRIIb polymorphism study.

Recombinant CHO-K1 cells stably overexpress Homo sapiens cell-type natural killer cells Fc gamma receptor IIc1 (FcγRIIc / CD32C) on the cell surface. The surface expression of FcγRIIc is validated by FACS analysis. This stable cell line is recommended for evaluating the binding affinity between FcγRIIc and Fc region of antibodies, Fc fusion proteins, or antibody-based biologics.

CD38 (cluster of differentiation 38), also known as cyclic ADP ribose hydrolase is a glycoprotein found on the surface of many immune cells (white blood cells), including CD⁴⁺, CD⁸⁺, B lymphocytes and natural killer cells. CD38 also functions in cell adhesion, signal transduction and calcium signaling. In humans, the CD38 protein is encoded by the CD38 gene which is located on chromosome 4. CD38 is a multifunctional ectoenzyme that catalyzes the synthesis and hydrolysis of cyclic ADP-ribose (cADPR) from NAD⁺to ADP-ribose. These reaction products are essential for the regulation of intracellular Ca²⁺.

Recombinant CHO-K1 cells stably overexpress high affinity human Fc fragment of IgG receptor Ia (FcγRI, CD64) on the cell surface, containing one alpha chain and two gamma chains. The surface expression of CD64 is validated by FACS analysis. This stable cell line product is designed for measuring the binding affinity and stability of the Fc region of antibodies, Fc fusion proteins, or antibody based biologics that bind with CD64 during biologics research and development.

Cluster of Differentiation 80 (also CD80 and B7-1) is a protein found on activated B cells and monocytes that provides a costimulatory signal necessary for T cell activation and survival. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells.

Claudins are a family of proteins, which play a role in maintaining tight cell junctions. Differentclaudin subtypes are expressed on different tissues.Claudin 18 isoform 2 (CLDN18.2) expressionin normal tissues is restricted to cells of the gastric mucosa and is absent from other healthytissues However, CLDN 18.2 is expressed in 70% of primary gastric adenocarcinomas and itsmetastases (101). It has also been shown to be expressed in a number of other cancers,including pancreatic (50%), esophagus (30%) and NSCLC (25%)The restricted expressionmakes it a potential drug target for the treatment of gastric and pancreatic adenocarcinoma, asevidenced by efforts to target CLDN18.2 via naked antibody and CAR-T modalities.

* The mycoplasma test was
performed with MycoAlert™ PLUS Mycoplasma Detection Kit of Lonza.

The orphan receptor ChemR23 (also referred to as CMKLR1 or DEZ) is a G-protein coupled receptor (GPCR) with homology to neuropeptide and chemoattractant receptors. ChemR23 is also a Gαi-linked receptor expressed primarily by monocytes, MΦs, and plasmacytoid dendritic cells. CMKLR1 has been shown to be expressed by DC generated in vitro from monocytes, to mediate their migration to the proteolytically regulated chemoattractant chemerin, and CMKLR1 may be a key mediator of pDC recruitment from the blood into tissue sites enriched in active chemerin.

This is a cell model with luciferase reporter gene for cell-based assay. CHO-K1/CRE-CBLuc/GLP1R Stable cell line is designed for In Vitro assay to detect the bioactivity of GLP-1 analogue. The binding affininity or the relative potency of the candidate drug can also be evaluated with this cell model.

The CRF1 receptor is a Gs-coupled GPCR expressed in the brain and pituitary gland that binds to several neuropeptides, including corticotropin-releasing factor (CRF) and urocortin, and the amphibian peptide sauvagine. CRF plays a predominant role in stress response mediated by the hypothalamic-pituitary-adrenal axis, and alterations in CRF and its receptors CRF1 and CRF2 appear to be linked to depression and anxiety. In comparison to the CRF2 receptor, the CRF1 receptor has received considerable attention as a potential therapeutic target for the treatment of stress-related disorders such as adrenocorticotropin hypersecretion, increased colonic motility and exaggerated fear and anxiety-related behavior.

The corticotropin-releasing factor receptor 2 CRF2 is Gs-coupled GPCRs expressed in the brain, blood vessels and intestine that bind to corticotropin-releasing factor (CRF). The CRF is a 41-amino acid peptide that plays an important role in the integration of autonomic, neuroendocrine, and behavioral responses to stress. GenScript’s cloned human CRF2-expressing cell line co-expressing Gα15 is made in the CHO-K1 host.

Numerous studies have demonstrated that the calcitonin receptor (CALCR) is a specific marker of osteoclast differentiation and that calcitonin can inhibit bone resorption in vitro and in vivo. Mice lacking calcitonin and calcitonin gene-related peptide (CGRP) have a high bone mass phenotype due to an increase in bone formation parameters. Expression of calcitonin (CT) and its receptor (CTR) generate survival, adhesion, pro-inflammatory, and pro-metastatic pathways. Moreover, data indicate a pivotal role for CT-CTR axis in advanced prostate cancer PC metastasis and may serve as a potential therapeutic target for advanced PC.

CTLA4 or CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), also known as CD152 (cluster of differentiation 152), is a protein receptor that functions as an immune checkpoint and downregulates immune responses. CTLA4 is constitutively expressed in regulatory T cells but only upregulated in conventional T cells after activation – a phenomenon which is particularly notable in cancers. It acts as an “off” switch when bound to CD80 or CD86 on the surface of antigen-presenting cells.

The CTLA-4 protein is encoded by the Ctla4 gene in mice and the CTLA4 gene in humans.

CXCR4 is a receptor for the C-X-C chemokine SDF-1 (Stromal Cell-Derived Factor 1). It is involved in haematopoiesis and cardiac ventricular septum formation, and plays an essential role in vascularization of the gastrointestinal tract, cerebellar development and survival of hippocampal-neuron of central nerve system. CXCR4 also acts as a primary receptor for some HIV-2 isolates and as a co-receptor with CD4 for HIV-1 X4 viruses.

4-1BB is a member of the tumor necrosis factor (TNF) receptor family. Its alternative names are tumor necrosis factor receptor superfamily member 9 (TNFRSF9), CD137 and induced by lymphocyte activation (ILA). It is currently of interest to immunologists as a co-stimulatory immune checkpoint molecule. 4-1BB can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, 4-1BB expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation.

BDCA-2 is a novel type II C-type lectin, which shows 50.7% sequence identity at the amino acid level to its putative murine ortholog, the murine dendritic cell–associated C-type lectin 2. In addition to its antigen capturing function, BDCA-2 can mediate potent inhibition of induction of IFN-α/β expression in PDCs. Production of IFN-α/β in response to several different types of viruses, bacteria, CpG-DNA, dsRNA, and SLE serum is by far the most prominent feature of PDCs.

BDCA-2 is a novel type II C-type lectin, which shows 50.7% sequence identity at the amino acid level to its putative murine ortholog, the murine dendritic cell–associated C-type lectin 2. In addition to its antigen capturing function, BDCA-2 can mediate potent inhibition of induction of IFN-α/β expression in PDCs. Production of IFN-α/β in response to several different types of viruses, bacteria, CpG-DNA, dsRNA, and SLE serum is by far the most prominent feature of PDCs.

CD155, commonly known as PVR (poliovirus receptor) and Necl-5 (nectin-like molecule-5), is a type I transmembrane single-span glycoprotein and belongs to the nectins and nectin-like (Necl) subfamily. CD155 was originally identified based on its ability to mediate the cell attachment and entry of poliovirus (PV), an etiologic agent of the central nervous system disease poliomyelitis. The normal cellular function is in the establishment of intercellular adherens junctions between epithelial cells. CD155 may assist in an efficient humoral immune response generated within the intestinal immune system. It’s been shown that CD155 can be recognized and bind by DNAM-1 and CD96, which promotes the adhension, migration, and NK-cell killing. Thus, inducing cell-mediated tumor-specific immunity.

This gene encodes a membrane protein, which is involved in the increase in intracellular calcium concentration that occurs upon cell adhesion to extracellular matrix. The encoded protein is also a receptor for the C-terminal cell binding domain of thrombospondin, and it may play a role in membrane transport and signal transduction. This gene has broad tissue, distribution, and is reduced in expression on Rh erythrocytes. Alternatively spliced transcript variants have been found for this gene.

CTLA4 or CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), also known as CD152 (cluster of differentiation 152), is a protein receptor that, functioning as an immune checkpoint, downregulates immune responses. CTLA4 is constitutively expressed in Tregs but only upregulated in conventional T cells after activation. It acts as an

HVEM is found on the surface of various cell types, including hematopoietic and non-hematopoietic cells, and is expressed mainly in spleen, thymus, bone marrow, lung and intestines. It has been identified as a canonical TNF receptor, signaling through the TNF receptor-associated factors (TRAFs) leading to NFκB activation. Furthermore, in addition to acting as a signaling receptor, in binding to Ig superfamily members it acts as a ligand for these inhibitory receptors. Therefore, bidirectional signaling is possible for the HVEM-mediated signaling network, which can be involved in positive or negative immunological reactions under different contexts.

Programmed cell death protein 1, also known as PD-1 and CD279 (cluster of differentiation 279), is a protein that in humans is encoded by the PDCD1 gene. PD-1, functioning as an immune checkpoint, plays an important role in down regulating the immune system by preventing the activation of T-cells, which in turn reduces autoimmunity and promotes self-tolerance. The inhibitory effect of PD-1 is accomplished through a dual mechanism of promoting apoptosis (programmed cell death) in antigen specific T-cells in lymph nodes while simultaneously reducing apoptosis in regulatory T cells (suppressor T cells).

Programmed death-ligand 1 (PD-L1) also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1) is a protein that in humans is encoded by the CD274 gene. The formation of PD-1 receptor / PD-L1 or B7.1 receptor /PD-L1 ligand complex transmits an inhibitory signal which reduces the proliferation of these CD8+ T cells at the lymph nodes. Supplementary to that PD-1 is also able to control the accumulation of foreign antigen specific T cells in the lymph nodes through apoptosis which is further mediated by a lower regulation of the gene Bcl-2.

Programmed cell death 1 ligand 2 (PD-L2) is a protein that is encoded by the PDCD1LG2 gene in humans. PDCD1LG2 has also been designated as CD273 (cluster of differentiation 273). Inhibitory molecules of the B7/CD28 family play a key role in the induction of immune tolerance in the tumor microenvironment. The programmed death-1 receptor (PD-1), with its ligands PD-L1 and PD-L2, constitutes an important member of these inhibitory pathways. PD-L2 expression was initially thought to be restricted to antigen-presenting cells such as macrophages and dendritic cells (DCs). However, PD-L2 expression can be induced on a wide variety of other immune cells and nonimmune cells depending on micro environmental stimuli.

V-domain Ig suppressor of T cell activation (VISTA) is a potent negative regulator of T-cell function that is expressed on hematopoietic cells. VISTA levels are heightened within the tumor microenvironment, in which its blockade can enhance antitumor immune responses in mice. In humans, blockade of the related programmed cell death 1 (PD-1) pathway has shown great potential in clinical immunotherapy trials.

CysLT1 (Cysteinyl leukotriene receptor 1) is previous named as LTD4 receptor (leukotriene D4 receptor). It is a receptor for cysteinyl leukotrienes and has highest affinity to leukotriene D4 (LTD4). The receptor mediates contraction and proliferation of smooth muscle, edema, eosinophil migration and damage to the mucus layer in the lung caused by LTD4. A CysLT1 selective antagonist, montelukast, is used clinically in the treatment of asthma.. This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system. The rank order of affinities for the leukotrienes is LTD4 >> LTE4 = LTC4 >> LTB4.

Dopamine is the predominant catecholamine neurotransmitter found in mammalian brain, where it controls a variety of functions including locomotor activity, cognition, emotion, positive reinforcement, food intake, and endocrine regulation. It also plays multiple roles in the periphery as a modulator of cardiovascular function, catecholamine release, hormone secretion, vascular tone, renal function, and gastrointestinal motility. The dopamine receptor family consists of five members, which are classified into two groups, D1-like (D1 and D5) and D2-like (D2, D3, and D4).

Dopamine is the predominant catecholamine neurotransmitter found in mammalian brain, where it controls a variety of functions including locomotor activity, cognition, emotion, positive reinforcement, food intake, and endocrine regulation. It also plays multiple roles in the periphery as a modulator of cardiovascular function, catecholamine release, hormone secretion, vascular tone, renal function, and gastrointestinal motility. The dopamine receptor family consists of five members, which are classified into two groups, D1-like (D1 and D5) and D2-like (D2, D3, and D4). Dopamine receptor 2 is mainly expressed in the brain. It has splicing variants, D2L and D2S. D2R receptor is implicated in a number of neurological and psychiatric conditions. Drugs acting at dopamine D2 receptors (D2R) are commonly used to alleviate symptoms for Parkinson’s disease, schizophrenia, and depression.

The short form of D2 (D2S) and the long form (D2L) are two isoforms that contribute differentially to dopamine signaling in both prefrontal cortex and striatum. The D2 dopamine receptor, short form (D2s) has been shown to stimulate phospholipase D (PLD) activity independent of the activation of phospholipase C (PLC) activity in GH4 derived cells stably transfected with the D2s receptor. Agonist activation of D2s has been shown to mediate the inhibition of growth in the same cell line.

Dopamine is the predominant catecholamine neurotransmitter found in mammalian brain, where it controls a variety of functions including locomotor activity, cognition, emotion, positive reinforcement, food intake, and endocrine regulation. It also plays multiple roles in the periphery as a modulator of cardiovascular function, catecholamine release, hormone secretion, vascular tone, renal function, and gastrointestinal motility. The dopamine receptor family consists of five members, which are classified into two groups, D1-like (D1 and D5) and D2-like (D2, D3, and D4). D5 receptor has a 10-fold higher affinity for dopamine than the D1 receptor.

DP1 is a G_s-coupled GPCR expressed in the colon, eye, platelets, eosinophils, that bind to PGD2 and PGE2. DP1 can inhibit platelet aggregation, and also inhibit leukotriene B4 and superoxide anion (O2-) release from human neutrophils. It can relax smooth muscle and regulate eosinophil apoptosis. DP receptor knockout OVA-challenged mice exhibit reduced Th2 cytokine levels and lymphocyte accumulation in the lung. In addition, they failed to produce asthmatic responses.

Prostaglandin D(2) (PGD(2)) is derived from arachidonic acid and binds with high affinity to the G-protein coupled receptors prostanoid DP(1) and DP(2). Interaction with DP(2) results in cell chemotaxis, eosinophil degranulation, eosinophil shape change, adhesion molecule upregulation and Th2 cytokine production. In allergic rhinitis and allergic asthma PGD(2) is released from mast cells in response to allergen challenge and may trigger symptoms such as sneezing, rhinorrhea, pruritus, mucus hypersecretion and pulmonary inflammation. GenScript’s cloned human DP2-expressing cell line co-expressing Gα15 is made in the CHO-K1 host.

In mammals, the endothelin (ET) family comprises three endogenous isoforms: ET-1, ET-2, and ET-3. These endothelium-derived peptides perform their functions via two endothelin receptors, classified as EDNRA and EDNRB. EDNRA receptors are mainly localized in the vascular smooth muscle cells, where they are the predominant sub-type, and mediate vasoconstriction and proliferation. Selective EDNRA antagonists are effective in the treatment of heart failure, essential hypertension, pulmonary hypertension, and atherosclerosis.

In mammals, the endothelin (ET) family comprises three endogenous isoforms: ET-1, ET-2, and ET-3. These endothelium-derived peptides perform their functions via two endothelin receptors, classified as EDNRA and EDNRB. EDNRB receptors present on the endothelial cells lining the vessel wall and play a role in the release of endothelium-derived relaxing factors such as nitric oxide (NO) and prostanoids and in removing ET from the circulation.

Prostaglandin (PG) E2 exerts its actions by acting on a group of G-protein-coupled receptors (GPCRs). There are four GPCRs responding to PGE2 designated subtypes EP1, EP2, EP3, and EP4 and multiple splicing isoforms of the subtype EP3. The EP subtypes exhibit differences in signal transduction, tissue localization, and expression regulation. Studies have identified that EP2 mediates many processes, such as facilitating ovulation and fertilization, suppressing dendritic cell differentiation, and promoting amyloid-β formation in Alzheimer’s disease.

Recombinant CHO-K1 cells stably overexpress human neonatal Fc receptor (FcRn) and beta-2 microglobulin (B2M). The existence of B2M enables the stable expression of FcRn. The surface expression of FcRn is validated by FACS analysis. This stable cell line product is designed for measuring binding affinity and stability of Fc region of antibodies, Fc fusion proteins, and antibody based biologics that binds with FcRn during biologics research and development.

Free fatty acid G protein coupled receptor family consists of four members and plays significant roles in nutrition regulation. GPR40 and GPR120 are activated by medium and long-chain FFAs, whereas GPR41 and GPR43 can be activated by short-chain FFAs. GPR40 is preferentially expressed in pancreatic beta-cells and mediates the majority of the effects of FFAs on insulin secretion. Researches show that GPR40 is a potential therapeutic target and plays an important role in the chain of events linking obesity and type2 diabetes.

FFA2 (GPR43) is a 330-amino acid G-protein coupled receptor that binds to fatty acid. FFA2 is highly selective expressed in leukocytes, which suggests a role in the recruitment of these cell populations toward sites of bacterial infection.

The formyl peptide receptors (FPR) are a class of G protein-coupled receptors involved in chemotaxis. FPR1 is a Gi-coupled GPCR. FPR1 is expressed in the vasculature, secretory epithelial cells, neurons and other tissues. FPR is involved in host defense against bacterial infection and in the clearance of damaged cells.

The FPR family members including FPR, formyl peptide receptor like-1 and -2 (FPRL1, FPRL2), are differently expressed in phagocytes with neutrophils expressing FPR and FPRL1 and monocytes/macrophages expressing all three. FPRL1 may constitute an additional molecular target for the development of therapeutic agents for Alzheimer’s disease (AD). GenScript has created a cell line that expresses FPRL1 in the CHO-K1 expressing Gα15.